Statin therapy in lupus-mediated atherogenesis: Two birds with one stone?

Annals of the Rheumatic Diseases

Volumn 70, Issue 2, 2011, Pages 245-248

  Van Leuven, Sander I ^a,b   Mendez Fernandez, Yanice V ^a   Stroes, Erik S ^b   Tak, Paul P ^b   Major, Amy S ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; APOLIPOPROTEIN A1; ATORVASTATIN; AZATHIOPRINE; CYCLOPHOSPHAMIDE; EZETEMIBE; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMIDAPRIL; L4 F PEPTIDE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METHOTREXATE; PRAVASTATIN; PREDNISONE; RAMIPRIL; ROSUVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

ARTERIAL WALL THICKNESS; ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CD4+ T LYMPHOCYTE; CELL INFILTRATION; DISEASE ASSOCIATION; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; ERYTHROCYTE SEDIMENTATION RATE; HUMAN; IMMUNOMODULATION; MAJOR HISTOCOMPATIBILITY COMPLEX; NONHUMAN; PRIORITY JOURNAL; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT DURATION; TREATMENT RESPONSE;

ANIMALS; ATHEROSCLEROSIS; DISEASE MODELS, ANIMAL; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MICE;

EID: 78751701952     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/ard.2010.133827     Document Type: Review

References (30)

1. Urowitz MB, Bookman AA, Koehler BE, et al. The bimodal mortality pattern of systemic lupus erythematosus. Am J Med 1976;60:221-5.
2. Hak AE, Karlson EW, Feskanich D, et al. Systemic lupus erythematosus and the risk of cardiovascular disease: results from the nurses' health study. Arthritis Rheum 2009;61:1396-402.
3. van Leuven SI, Kastelein JJ, D'Cruz DP, et al. Atherogenesis in rheumatology. Lupus 2006;15:117-21.
4. Esdaile JM, Abrahamowicz M, Grodzicky T, et al. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum 2001;44:2331-7.
5. van Leuven SI, Franssen R, Kastelein JJ, et al. Systemic inflammation as a risk factor for atherothrombosis. Rheumatology (Oxford) 2008;47:3-7. (Pubitemid 350286254)
6. Petri M, Perez-Gutthann S, Spence D, et al. Risk factors for coronary artery disease in patients with systemic lupus erythematosus. Am J Med 1992;93:513-19.
7. Rahman P, Aguero S, Gladman DD, et al. Vascular events in hypertensive patients with systemic lupus erythematosus. Lupus 2000;9:672-5. (Pubitemid 32011792)
8. Bruce IN, Urowitz MB, Gladman DD, et al. Natural history of hypercholesterolemia in systemic lupus erythematosus. J Rheumatol 1999;26:2137-43.
9. Urowitz MB, Gladman DD, Ibanez D, et al. Modification of hypertension and hypercholesterolaemia in patients with systemic lupus erythematosus: a quality improvement study. Ann Rheum Dis 2006;65:115-17. (Pubitemid 41815651)
10. Adkim F, van Leuven SI, Kastelein JJ, et al. Pleiotropic effects of statins: stabilization of the vulnerable atherosclerotic plaque? Curr Pharm Des 2007;13:1003-12.
11. Greenwood J, Steinman L, Zamvil SS. Statin therapy and autoimmune disease: from protein prenylation to immunomodulation. Nat Rev Immunol 2006;6:358-70.
12. Lawman S, Mauri C, Jury EC, et al. Atorvastatin inhibits autoreactive B cell activation and delays lupus development in New Zealand black/white F1 mice. J Immunol 2004;173:7641-6. (Pubitemid 39628206)
13. Graham KL, Lee LY, Higgins JP, et al. Failure of oral atorvastatin to modulate a murine model of systemic lupus erythematosus. Arthritis Rheum 2008;58:2098-104.
14. Shimazu H, Kinoshita K, Hino S, et al. Effect of combining ACE inhibitor and statin in lupus-prone mice. Clin Immunol 2010;136:188-96.
15. Aprahamian T, Bonegio R, Rizzo J, et al. Simvastatin treatment ameliorates autoimmune disease associated with accelerated atherosclerosis in a murine lupus model. J Immunol 2006;177:3028-34. (Pubitemid 44277819)
16. Woo JM, Lin Z, Navab M, et al. Treatment with apolipoprotein A-1 mimetic peptide reduces lupus-like manifestations in a murine lupus model of accelerated atherosclerosis. Arthritis Res Ther 2010;12:R93.
17. Abud-Mendoza C, de la Fuente H, Cuevas-Orta E, et al. Therapy with statins in patients with refractory rheumatic diseases: a preliminary study. Lupus 2003;12:607-11.
18. Kotyla PJ, Sliwinska-Kotyla B, Kucharz EJ. Tumor necrosis factor-alpha as a potential target in the treatment of systemic lupus erythematosus: a role for the HMG-CoA reductase inhibitor simvastatin. J Rheumatol 2006;33:2361-3.
19. Kotyla PJ. Comment on: atorvastatin therapy improves endothelial- dependent vasodilation in patients with systemic lupus erythematosus: an 8 week controlled trial. Rheumatology (Oxford) 2008;47:381-2.
20. Costenbader KH, Liang MH, Chibnik LB, et al. A pravastatin dose-escalation study in systemic lupus erythematosus. Rheumatol Int 2007;27:1071-7.
21. de Kruif MD, Limper M, Hansen HR, et al. Effects of a 3-month course of rosuvastatin in patients with systemic lupus erythematosus. Ann Rheum Dis 2009;68:1654.
22. Ferreira GA, Navarro TP, Telles RW, et al. Atorvastatin therapy improves endothelial-dependent vasodilation in patients with systemic lupus erythematosus: an 8 weeks controlled trial. Rheumatology (Oxford) 2007;46:1560-5.
23. Ferreira GA, Teixeira AL, Sato EI. Atorvastatin therapy reduces interferon-regulated chemokine CXCL9 plasma levels in patients with systemic lupus erythematosus. Lupus 2010;19:927-34.
24. El-Magadmi M, Bodill H, Ahmad Y, et al. Systemic lupus erythematosus: an independent risk factor for endothelial dysfunction in women. Circulation 2004;110:399-404. (Pubitemid 38993848)
25. Vera-Lastra O, Mendez OL, Jara LJ, et al. Effects of ezetimibe plus pravastatin on endothelial dysfunction in patients with systemic lupus erythematosus (pilot study) [abstract]. Arthritis Rheum 2009;60 (Suppl 10):1564.
26. Costenbader KH, Karlson EW, Gall V, et al. Barriers to a trial of atherosclerosis prevention in systemic lupus erythematosus. Arthritis Rheum 2005;53:718-23.
27. Petri M, Kiani AN, Post W, et al. Lupus Atherosclerosis Prevention Study (LAPS): a randomized double blind placebo controlled trial of atorvastatin versus placebo [abstract]. Arthritis Rheum 2006;54 (>Suppl 9):S520.
28. McCullough PA, Chinnaiyan KM. Annual progression of coronary calcification in trials of preventive therapies: a systematic review. Arch Intern Med 2009;169:2064-70.
29. Sandborg C, Ardoin SP, Schanberg L. Therapy Insight: cardiovascular disease in pediatric systemic lupus erythematosus. Nat Clin Pract Rheumatol 2008;4:258-65.
30. Norby GE, Holme I, Fellström B, et al.; Assessment of Lescol in Renal Transplantation Study Group. Effect of fluvastatin on cardiac outcomes in kidney transplant patients with systemic lupus erythematosus: a randomized placebo-controlled study. Arthritis Rheum 2009;60:1060-4